TP53 and myeloproliferative neoplasm: In keeping with their established prognostic role across myeloid neoplasms, mutations in so-called “high molecular risk” (HMR) associated genes (ASXL1, TP53, EZH2, and SRSF2), have been shown to keep an adverse influence on survival in MPN-BP [6,27,28,29].